ArticleScientific reports2025
Discovery of potent endolysins against Pseudomonas aeruginosa and other gram-negative ESKAPE pathogens by an agar-based screening method.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic resistance is a growing concern, and there is an urgent need for alternative treatments. A proposed solution includes endolysins. Naturally occurring endolysins have limited activity against Gram-negative bacteria due to the presence of an outer membrane. Previous agar-based screening methods did not consider this and screened for activity on autoclaved cell debris. In this study, we used a soft-agar-based screening method to identify endolysins targeting Pseudomonas aeruginosa. This method enabled us to screen for activity of endolysins on live Pseudomonas aeruginosa, taking the outer membrane into account. The application of this randomized forward screening method led to the discovery of three highly bactericidal endolysins, L0779, L0782, and L0799. These endolysins displayed a broad spectrum of activity against other Gram-negative bacterial species. We report minimal inhibitory concentrations (MICs) for endolysins acting on multiple Gram-negative ESKAPE species, with MICs for L0782 on Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii ranging from 4 to 16 µg/mL. In summary, our screening method enables rapid identification of endolysins with broad-spectrum activity against Gram-negative bacteria. These show potential for further development as alternative treatments for antibiotic-resistant infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.